Teva Pharma Is ‘Ideal Partner,’ Mesoblast CEO Itescu Says

Teva Pharmaceutical Industries Ltd. (TEVA) is an “even more of an ideal partner” than Cephalon Inc. (CEPH) to develop stem cell-based treatments, Mesoblast Ltd. (MSB) Chief Executive Officer Silviu Itescu said.

Teva, the world’s largest generic-drug maker, agreed yesterday to buy Cephalon for $6.8 billion, trumping a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) Cephalon owns 19.99 percent of Melbourne-based Mesoblast.

Teva is “a much larger specialty pharmaceutical company looking to build themselves into a biologics leader,” Itescu said in a telephone interview today.

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.